CADL
USDCandel Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$5.030
Kõrge
$5.270
Madal
$5.030
Maht
0.50M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
281.6M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.77M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and CEO, will present the phase 3 clinical trial of
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies
Stephens & Co. Initiates Coverage On Candel Therapeutics with Overweight Rating, Announces Price Target of $15
Stephens & Co. analyst Sudan Loganathan initiates coverage on Candel Therapeutics with a Overweight rating and announces Price Target of $15.
LifeSci Capital Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $16
LifeSci Capital initiates coverage on Candel Therapeutics with a Outperform rating and announces Price Target of $16.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.